Kurzfassung

A phase 3, double-blind, placebo-controlled study of Quizartinib (AC220) administered in combination with índuction and consolidation chemotherapy, and administered as naintenance therapy in subjects 18 to 75 years old with newly diagnosed FLT3-ITD (+) acute myeloid leukemia